文献速递糖尿病肥胖与代谢综合征

肠道菌群与糖尿病:研究、转化与临床应用——2023年《Diabetes》、《Diabetes Care》与《Diabetologia》专家论坛

The gut microbiota and diabetes: research, translation, and clinical applications - 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum.
PubMed 文献 · Diabetologia · 2024-06-24

本文总结由《Diabetes》、《Diabetes Care》和《Diabetologia》组织的国际专家论坛(2023年欧洲糖尿病研究协会年会,德国汉堡)关于肠道菌群在糖尿病中作用的科学现状。论坛结论包括:肠道菌群可能参与2型糖尿病病理生理;其高度个体化是主要研究障碍,需大型队列和深度测序宏基因组方法;未来需个体内重复采样研究;将知识应用于糖尿病诊断和治疗需大量未来研究及新技术和计算工具。

要点

  • 肠道菌群可能参与2型糖尿病病理生理,微生物代谢物与疾病正负相关。
  • 肠道菌群高度个体化是主要研究障碍,需大型队列和深度测序宏基因组方法。
  • 未来需个体内重复测量研究,并需新技术和计算工具推动临床转化。

核心结论

  • 肠道菌群可能参与2型糖尿病病理生理,微生物产生的代谢物与疾病呈正相关和负相关,且通过人类孟德尔随机化已揭示肠道菌群功能(如丁酸产生基因)与葡萄糖代谢的机制联系。

研究设计与样本

  • 本文为国际专家论坛总结,论坛由《Diabetes》、《Diabetes Care》和《Diabetologia》组织,于2023年欧洲糖尿病研究协会年会在德国汉堡举行。
  • 论坛参与者包括肠道微生物组与代谢领域的领先临床医生和基础科学家。

主要发现

  • 肠道菌群的高度个体化性质构成主要研究障碍,需大型队列和深度测序宏基因组方法进行稳健的关联和因果评估。
  • 单时间点采样遗漏个体内肠道菌群动态,未来需个体内重复测量的研究。
  • 将不断扩展的知识应用于糖尿病诊断和治疗需大量未来研究,新技术和改进的计算工具对实现该目标很重要。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 肠道菌群的高度个体化性质构成主要研究障碍。
  • 单时间点采样遗漏个体内肠道菌群动态。
  • 将不断扩展的知识应用于糖尿病诊断和治疗需大量未来研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This article summarises the state of the science on the role of the gut microbiota (GM) in diabetes from a recent international expert forum organised by Diabetes, Diabetes Care, and Diabetologia, which was held at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany. Forum participants included clinicians and basic scientists who are leading investigators in the field of the intestinal microbiome and metabolism. Their conclusions were as follows: (1) the GM may be involved in the pathophysiology of type 2 diabetes, as microbially produced metabolites associate both positively and negatively with the disease, and mechanistic links of GM functions (e.g. genes for butyrate production) with glucose metabolism have recently emerged through the use of Mendelian randomisation in humans; (2) the highly individualised nature of the GM poses a major research obstacle, and large cohorts and a deep-sequencing metagenomic approach are required for robust assessments of associations and causation; (3) because single time point sampling misses intraindividual GM dynamics, future studies with repeated measures within individuals are needed; and (4) much future research will be required to determine the applicability of this expanding knowledge to diabetes diagnosis and treatment, and novel technologies and improved computational tools will be important to achieve this goal.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Byndloss M, Devkota S, Duca F, et al. The gut microbiota and diabetes: research, translation, and clinical applications - 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum. Diabetologia. 2024. PMID: 38910152. doi:10.1007/s00125-024-06198-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。